Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy

被引：0
|
作者：
Fazio, Francesca [1 ]
Di Rocco, Alice [1 ]
Za, Tommaso [2 ]
Tomarchio, Valeria [3 ]
Rago, Angela [4 ]
Piciocchi, Alfonso [5 ]
di Toritto, Tommaso Caravita
Annibali, Ombretta [3 ]
De Stefano, Valerio [2 ]
Foa, Robin [1 ]
Martelli, Maurizio [1 ]
Petrucci, Maria Teresa [1 ]
机构：
[1] Sapienza Univ Rome, Dept Translat & Precis Med, Azienda Osped Policlin Umberto 1, Hematol, Rome, Italy
[2] Catholic Univ, Sect Hematol, Dept Radiol & Hematol Sci, Fdn Policlin A Gemelli, Rome, Italy
[3] Univ Campus Bio Medico, Hematol Unit, Stem Cell Transplantat, Rome, Italy
[4] UOSD Ematol ASL Roma 1, Rome, Italy
[5] Italian Grp Adult Hematol Dis GIMEMA, Rome, Italy
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-149547
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3755
引用
收藏
页码：3755 / +
页数：5
相关论文
共 50 条
  • [41] A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
    Zhang, Hua
    Gao, Lei
    Liu, Li
    Wang, Jishi
    Wang, Sanbin
    Gao, Li
    Zhang, Cheng
    Liu, Yao
    Kong, Peiyan
    Liu, Jia
    He, Jiaping
    Han, Yu
    Shi, Hua
    He, Yan
    Ye, Xun
    Zhao, Yi
    Cao, Wei
    Shen, Lianjun
    Zhang, Xi
    BLOOD, 2019, 134
  • [42] Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
    Martin, Thomas G.
    Madduri, Deepu
    Pacaud, Lida
    Usmani, Saad Z.
    FUTURE ONCOLOGY, 2023, 19 (34) : 2297 - 2311
  • [43] Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
    Davis, James A.
    Dima, Danai
    Ahmed, Nausheen
    DeJarnette, Shaun
    McGuirk, Joseph P.
    Khouri, Jack
    Valent, Jason
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
  • [44] Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
    Kambhampati, Swetha
    Sheng, Ying
    Huang, Chiung-Yu
    Bylsma, Sophia
    Lo, Mimi
    Kennedy, Vanessa
    Natsuhara, Kelsey
    Martin, Thomas
    Wolf, Jeffrey
    Shah, Nina
    Wong, Sandy W.
    BLOOD ADVANCES, 2022, 6 (07) : 2045 - 2054
  • [45] BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement
    Wang, Yiyun
    Zu, Cheng
    Teng, Xinyi
    Yang, Li
    Zhang, Mingming
    Hong, Ruimin
    Zhao, Houli
    Cui, Jiazhen
    Xu, Huijun
    Hongsheng, Alex Chang
    Hu, Yongxian
    Huang, He
    JOURNAL OF IMMUNOTHERAPY, 2022, 45 (01) : 25 - 34
  • [46] Healthcare resource utilization and costs among patients with relapsed/refractory multiple myeloma treated with chimeric antigen receptor-T (CAR-T) cell therapy
    Jagannath, Sundar
    Kharat, Akshay
    Fu, Alex
    Huo, Stephen
    Kohli, Monal
    Adams, Shayna
    Umeh, Emeka
    Foster, Miran
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S187 - S188
  • [47] Healthcare Resource Utilization and Costs Among Patients With Relapsed/Refractory Multiple Myeloma Treated With Chimeric Antigen Receptor-T (CAR-T) Cell Therapy
    Jagannath, Sundar
    Kharat, Akshay
    Fu, Alex
    Huo, Stephen
    Kohli, Monal
    Adams, Shayna
    Umeh, Emeka
    Foster, Miran
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S511 - S512
  • [48] Current Status of CAR-T Cell Therapy in Multiple Myeloma
    Reguera-Ortega, Juan Luis
    Garcia-Guerrero, Estefania
    Perez-Simon, Jose Antonio
    HEMATO, 2021, 2 (04): : 660 - 671
  • [49] Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy
    Cheng, Hai
    Sun, Yingjun
    Zhang, Xiaoxue
    Chen, Zihan
    Shao, Lingyan
    Liu, Jiaying
    Wang, Dandan
    Chen, Yegan
    Wang, Xue
    Chen, Wei
    Sang, Wei
    Qi, Kunming
    Li, Zhenyu
    Sun, Cai
    Shi, Ming
    Qiao, Jianlin
    Wu, Qingyun
    Zeng, Lingyu
    Zheng, Junnian
    Xu, Kailin
    Cao, Jiang
    CYTOTHERAPY, 2024, 26 (08) : 832 - 841
  • [50] Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
    Costa, Luciano J.
    Lin, Yi
    Cornell, R. Frank
    Martin, Thomas
    Chhabra, Saurabh
    Usmani, Saad Z.
    Jagannath, Sundar
    Callander, Natalie S.
    Berdeja, Jesus G.
    Kang, Yubin
    Vij, Ravi
    Godby, Kelly N.
    Malek, Ehsan
    Neppalli, Amarendra
    Liedtke, Michaela
    Fiala, Mark
    Tian, Hong
    Valluri, Satish
    Marino, Jennifer
    Jackson, Carolyn C.
    Banerjee, Arnob
    Kansagra, Ankit
    Schecter, Jordan M.
    Kumar, Shaji
    Hari, Parameswaran
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05): : 326 - 335
12345